Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_assertion type Assertion NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_head.
- NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_provenance.
- NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_assertion evidence source_evidence_literature NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_provenance.
- NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_assertion SIO_000772 10436809 NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_provenance.
- NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_assertion wasDerivedFrom befree-20150227 NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_provenance.
- NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_assertion wasGeneratedBy ECO_0000203 NP651207.RA0S0pG_Curx2OPrdGLybOXdGWgA0ahjVfCB4HJQ_j1BA130_provenance.